In addition, screening of multiple myeloma surface antigens has identified other promising targets, including CD28 (Tp44), CD48 (BLAST), CD74 (CLIP), CD138 (SDC1), CD229 (SLAMF3), CD319 (SLAMF7), CCR10 (GPR2), TAC1 (NPK), TXNDC11, SLC1A5 (AAAT) [36]. This evidence concerns the gene CD28 and plasma cell myeloma.